SAlthough the historical successes of French biomedical research are numerous, the indicators show a significant decline in the world ranking since 2005. However, environmental impacts, emerging diseases, population aging and artificial intelligence are just a few examples of challenges that must be faced to health from tomorrow.

Biomedical research in France is divided into three main actors: universities, hospitals and university centers (CHU) and research organizations – most notably the National Institute of Health and Medical Research (Inserm), which has just been given the task of programming health research at the national level.

Since the reform of 1958, this research has always been considered an essential and strategic task of university hospitals, reinforced by the law of July 21, 2009 on hospital reform and in relation to patients.

Triptych CHU universities research organizations

Although the Hospital, Patients, Health and Territorial Act (HPST, 2009) aimed to strengthen the collaboration of the various actors in hospital-university research, it encountered a lack of visibility and collaboration at the national level and particularly between CHUs Vice Presidents for research on the boards of university hospitals.

Since the Research Vice President is in fact almost always a hospital-university practitioner affiliated with a research organization, he ensures the coherence and complementarity of the actions of the CHUs with those of the universities and research organizations, thus allowing a smooth transition between basic research, translational and clinical research based on nursing issues.

In the interest of implementing a pragmatic and coordinated research policy, the vice presidents of the university hospitals responsible for research have decided to join forces in a national council. Its mission is to develop and promote biomedical research within university hospitals, structures that are closely linked to mixed university research units and are ideally positioned at the interface between care, clinical research and innovation.

Its aim is to participate in the development of strategic proposals common to the triptych CHU-universities-research organizations in favor of biomedical research. We take on a social role and would also like to participate in disseminating the questions, methods and results of biomedical research to the general public.

You still have 70% of this article left to read. The rest is reserved for subscribers.